Ancillary product patents to extend biologic patent life

JAMA

13 November 2023 - In 2021, 46% ($260 billion) of all gross prescription drug spending in the US was on biologic products.

Patents are government-granted monopolies that last 20 years; by obtaining multiple patents for different aspects of the same product, biologic manufacturers create “patent thickets” that can block or delay biosimilar competition to protect market share.

Read JAMA Research Letter

Michael Wonder

Posted by:

Michael Wonder